v3.25.2
Condensed consolidated statement of cash flows - USD ($)
$ in Millions
6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Cash flows from operating activities    
Profit before tax $ 6,529 $ 5,197
Finance income and expense 636 645
Share of after tax losses of associates and joint ventures 17 19
Depreciation, amortisation and impairment 2,673 2,534
Movement in working capital and short-term provisions (771) (584)
Gains on disposal of intangible assets (87) (21)
Fair value movements on contingent consideration arising from business combinations (30) 251
Non-cash and other movements 304 (550)
Cash generated from operations 9,271 7,491
Interest paid (623) (583)
Tax paid (1,549) (1,337)
Net cash inflow from operating activities 7,099 5,571
Cash flows from investing activities    
Acquisition of subsidiaries, net of cash acquired   (2,771)
Payment of contingent consideration from business combinations (629) (474)
Purchase of property, plant and equipment (1,088) (799)
Disposal of property, plant and equipment 10 53
Purchase of intangible assets (1,804) (1,474)
Disposal of intangible assets 95 75
Purchase of non-current asset investments (188) (67)
Disposal of non-current asset investments   51
Movement in short-term investments, fixed deposits and other investing instruments 115 42
Payments to associates and joint ventures   (140)
Disposal of investments in associates and joint ventures   13
Interest received 128 206
Net cash outflow from investing activities (3,361) (5,285)
Net cash inflow before financing activities 3,738 286
Cash flows from financing activities    
Proceeds from issue of share capital 12 11
Own shares purchased by Employee Benefit Trust (489)  
Payments to acquire non-controlling interests (2)  
Issue of loans and borrowings 9 4,976
Repayment of loans and borrowings (16) (2,643)
Dividends paid (3,357) (3,050)
Hedge contracts relating to dividend payments 104 (8)
Repayment of obligations under leases (184) (150)
Movement in short-term borrowings 1,734 2,503
Payment of Acerta Pharma share purchase liability   (833)
Net cash (outflow)/inflow from financing activities (2,189) 806
Net increase in Cash and cash equivalents in the period 1,549 1,092
Cash and cash equivalents at the beginning of the period 5,429 5,637
Exchange rate effects 54 (52)
Cash and cash equivalents at the end of the period 7,032 6,677
Cash and cash equivalents 7,058 6,916
Overdrafts $ (26) $ (239)